356 related articles for article (PubMed ID: 31361154)
1. Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC; Ngan RK; Cheung KM; Cho WC
Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
[No Abstract] [Full Text] [Related]
2. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review).
Huang H; Yao Y; Deng X; Huang Z; Chen Y; Wang Z; Hong H; Huang H; Lin T
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37417358
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
Dasari V; Sinha D; Neller MA; Smith C; Khanna R
Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic.
Raghupathy R; Hui EP; Chan AT
Am Soc Clin Oncol Educ Book; 2014; ():149-53. PubMed ID: 24857071
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
9. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
Lee AZE; Tan LSY; Lim CM
Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.
Masmoudi A; Toumi N; Khanfir A; Kallel-Slimi L; Daoud J; Karray H; Frikha M
Cancer Treat Rev; 2007 Oct; 33(6):499-505. PubMed ID: 17544585
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of LOX-1
Li X; Li JL; Jiang N; Chen J; Liang ZM; Zhao ZL; Xing YF
Aging (Albany NY); 2020 Dec; 13(1):437-449. PubMed ID: 33290259
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma.
Renaud S; Lefebvre A; Mordon S; Moralès O; Delhem N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560253
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for nasopharyngeal cancer-a review.
Jain A; Chia WK; Toh HC
Chin Clin Oncol; 2016 Apr; 5(2):22. PubMed ID: 27121882
[TBL] [Abstract][Full Text] [Related]
14. Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients.
Shen Y; Zhang S; Sun R; Wu T; Qian J
Emerg Microbes Infect; 2015 Mar; 4(3):e20. PubMed ID: 26038769
[TBL] [Abstract][Full Text] [Related]
15. EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules.
Liu Y; Lui KS; Ye Z; Fung TY; Chen L; Sit PY; Leung CY; Mak NK; Wong KL; Lung HL; Tanaka Y; Cheung AKL
Theranostics; 2023; 13(2):458-471. PubMed ID: 36632221
[TBL] [Abstract][Full Text] [Related]
16. The Role of NK Cells in EBV Infection and EBV-Associated NPC.
Png YT; Yang AZY; Lee MY; Chua MJM; Lim CM
Viruses; 2021 Feb; 13(2):. PubMed ID: 33671917
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.
Han S; Tay JK; Loh CJL; Chu AJM; Yeong JPS; Lim CM; Toh HC
Front Immunol; 2021; 12():734293. PubMed ID: 34956172
[TBL] [Abstract][Full Text] [Related]
18. Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities.
Lenoci D; Resteghini C; Serafini MS; Pistore F; Canevari S; Ma B; Cavalieri S; Alfieri S; Trama A; Licitra L; De Cecco L
Transl Res; 2024 Mar; 265():1-16. PubMed ID: 37949350
[TBL] [Abstract][Full Text] [Related]
19. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
